

**Cancer Cell, Volume 41**

**Supplemental information**

**Tumor dynamics in patients with solid  
tumors treated with pembrolizumab  
beyond disease progression**

**Brian G. Topp, Madhav Channavazzala, Kapil Mayawala, Dinesh P. De Alwis, Eric Rubin, Alexandra Snyder, Jedd D. Wolchok, and Antoni Ribas**


## SUPPLEMENT

**Table SA1** Sum of Target Lesion Diameters and ORR per RECIST v1.1 in the Postprogression Period Among Patients Who Were TBP, related to Table 1


	<b>SLD &gt;20%</b>	<b>SLD &lt;+20% to ≥30%</b>	<b>SLD &lt;30%</b>	<b>ORR, %</b>	<b>Time to SLD &lt;30%, median (range), weeks</b>	<b>TBP, median (range), weeks</b>
Melanoma (KEYNOTE-001)	10.7%	64.8%	24.4%	8.6%	12.0 (4.4-120.0)	18.4 (4.0-194.9)
NSCLC (KEYNOTE-001)	15.7%	72.6%	11.6%	2.8%	9.4 (7.9-64.1)	12.5 (4.0-90.4)
Gastric cancer (KEYNOTE-059)	18.4%	68.9%	12.6%	1.1%	12.1 (5.3-54.0)	6.1 (4.0-72.7)
HNSCC (KEYNOTE-048)	15.2%	75.9%	8.9%	0.9%	11.9 (6.0-39.4)	12.0 (4.0-150.4)
ccRCC (KEYNOTE-427)	11.8%	72.5%	15.7%	9.8%	18.0 (6.0-47.7)	17.6 (4.0-108.7)
UC (KEYNOTE-052)	13.6%	74.4%	12.0%	7.2%	12.0 (5.1-51.0)	10.6 (4.1-176.0)
UC (KEYNOTE-361)	8.8%	76.5%	14.7%	2.9%	15.7 (5.1-131.0)	12.9 (4.0-154.3)

Abbreviations: ccRCC, clear-cell renal cell carcinoma; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; ORR, objective response rate; SLD, sum of lesion diameters; UC, urothelial carcinoma.


**Fig SA1.** Inclusion criteria for patients, related to Figure 1. (A) melanoma, (B) NSCLC, (C) gastric cancer, (D) HNSCC, (E) ccRCC, (F) UC in KEYNOTE-052, and (G) UC in KEYNOTE-361ccRCC, clear-cell renal cell carcinoma; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; PD, progressive disease; UC, urothelial carcinoma.



**Fig SA2.** Normalized Waterfall plots comparing patients included and excluded for TBP, related to Figure 2. (A) Melanoma, (B) NSCLC, (C) gastric cancer, (D) HNSCC, (E) ccRCC, (F) UC KEYNOTE-52, (G) UC KEYNOTE-361. ccRCC, clear-cell renal cell carcinoma; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; UC, urothelial carcinoma.



**Fig SA3.** Best overall response and time on trial after progression for patients, related to Figure 2. (A, B) HNSCC, (C, D) ccRCC, (E,F) UC in KEYNOTE-052, and (G,H) UC in KEYNOTE-361. ccRCC, clear-cell renal cell carcinoma; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; PD, progressive disease; UC, urothelial carcinoma.



**Fig SA4.** Distribution of target lesion responses in preprogression and postprogression periods for patients with HNSCC, ccRCC, and UC, related to Figure 3. ccRCC, clear-cell renal cell carcinoma; HNSCC, head and neck squamous cell carcinoma; UC, urothelial carcinoma.

